GYRE Overview

Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.

Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Gyre Therapeutics Inc revenue for the last quarter amounts to 30.56M USD, increased 19.92

Gyre Therapeutics Inc. EPS for the last quarter amounts to 0.03 USD, increased 200.00

Gyre Therapeutics Inc (GYRE) has 574 emplpoyees as of March 11 2026.

Today GYRE has the market capitalization of 738.03M USD.